ASCO Annual Meeting

In a phase 1 study, anti-tumor responses were induced with PRT811 treatment in patients with recurrent, high-grade glioma and advanced or metastatic uveal melanoma.

Sara Tolaney, MD, MPH, discusses sacituzumab govitecan-hziy as an effective and safe treatment for patients with hormone receptor-positive/HER2-negative metastatic breast cancer.

Data from CheckMate 9LA trial further support the use of nivolumab plus ipilimumab and chemotherapy as an efficacious first-line treatment option for patients with metastatic NSCLC, says David P. Carbone, MD, PhD.

New data show the promise for use of tovorafenib to reduce pre-treated pediatric patients with a low-grade glioma.

In the combination of fianlimab and cemiplimab, we showed a consistent and reproducible high clinical activity in 3 independent cohorts of patients who were naive to anti–PD-1 in the advanced melanoma setting, says Omid Hamid, MD.

Patients with non–small cell lung cancer who completed definitive surgery saw clinical benefits after being treated with neoadjuvant nivolumab and chemotherapy.

New findings with the gamma secretase inhibitor nirogacestat show pain reduction for patients with desmoid tumors.

Preliminary results from the phase 1/2 ARTEMIDE-01 trial show the potential for PD-1 and TIGIT bispecific agent rilvegostomig in patients with advanced or metastatic PD-L1–positive non–small cell lung cancer.

Results from the DESTINY-CRC02 study showed that a lower dose of trastuzumab deruxtecan elicited promising results for patients with HER2-positive metastatic colorectal cancer vs a higher dose of the therapy.

New patient reported outcomes from the phase 3 RUBY trial show patients with primary advanced or recurrent endometrial cancer maintained their health-related quality of life when on dostarlimab and chemotherapy.

Results from the TALAPRO-2 study highlight the potential for the first-line treatment of patients with homologous recombination repair altered metastatic castration-resistant prostate cancer.

When comparing patients with metastatic castration-resistant prostate cancer who have homologous recombination repair deficiency mutations, those with BRCA mutations have worse outcomes compared to patients without the BRCA mutation in their disease.

Promising results reported from a study of GC012F in patients with relapsed or refractory multiple myeloma, warrant further research.

Katherine B. Peters, MD, PhD, discusses the findings from the phase 3 INDIGO trial which were presented at the 2023 ASCO annual meeting.

The results of vorasidenib signal potential for the agent to become the first targeted therapy in low-grade glioma.

The same high cure rates achieved with preoperative chemoradiation can be achieved with preoperative FOLFOX, according to Deb Schrag, MD, FASCO, MPH.

Kathleen N. Moore, MD says the phase 3 MIRASOL results bring a new standard-of-care to the FRα-high, platinum-resistant ovarian cancer landscape.

Pooled findings from MagnetisMM studies show the elranatamab has early activity in relapsed or refractory multiple myeloma.

ADAURA is the first global phase 3 study to demonstrate statistically significant and clinically meaningful disease-free survival and overall survival benefit with adjuvant targeted therapy for patients with EGFR-mutated, stage IB to IIIA NSCLC.

At the second planned interim analysis of the phase 3 SWOG S1826, the primary progression-free survival end point crossed the protocol-specified statistical boundary.

The immunotherapy and tyrosine kinase inhibitor combination cabozantinib plus nivolumab and piplimumab induces response in nearly half of patients treated.

A subgroup analysis of ENGOT-EN6-NSGO/GOG-3031/RUBY has displayed positivity efficacy in patients with advanced/recurrent endometrial cancer.

MD Anderson Cancer Center's Hans C. Lee, MD has presented promising results from the phase 2 LINKER-MM1 study at ASCO.

CLDN6-directed CAR T-cell therapy used with or without a CLDN6-encoding mRNA vaccine continues to show promise in advanced solid tumors.

The first study of a dual bispecific combination in relapsed or refractory multiple myeloma encourages the investigators.

Now that positive phase 1 results have been reported for PHE855, a phase 2 study of PHE855 is currently underway in patients with relapsed and refractory multiple myeloma.

Positive results have been reported from phase 1/2 KEYMAKER-U03B study, and belzutifan plus lenvatinib is being further investigated in the phase 3 LITESPARK-011 study (NCT04586231).

TALAPRO-2 is the first phase 3 study to evaluate talazoparib plus enzalutamide as a first-line treatment in patients with metastatic castration resistant prostate cancer.

Dennis J. Slamon, MD, discusses the key findings from the phase 3 NATALEE trial of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer.

News from KEYNOTE-671 in early-stage non–small cell lung cancer provides more evidence to support the FDA approval application for perioperative pembrolizumab.